Skip to content

Deep Subgluteal Block vs PENG Combined With LFCN Block for Analgesia After Hip Arthroplasty

Comparison of Deep Subgluteal Block and Pericapsular Nerve Group Block Combined With Lateral Femoral Cutaneous Nerve Block for Postoperative Analgesia After Hip Arthroplasty: A Randomized Prospective Study

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07770932
Acronym
DSG-PENG
Enrollment
60
Registered
2026-08-18
Start date
2026-08-01
Completion date
2027-01-30
Last updated
2026-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative Pain

Keywords

Deep Subgluteal Block PENG Block Lateral Femoral Cutaneous Nerve Block Hip Arthroplasty Nerve Block Opioid Consumption

Brief summary

This randomized, prospective study aims to compare the clinical efficacy of ultrasound-guided Deep Subgluteal Block (DSGB) versus Pericapsular Nerve Group (PENG) block combined with Lateral Femoral Cutaneous Nerve (LFCN) block for postoperative analgesia management in patients undergoing hip arthroplasty. A total of 60 patients scheduled for hip arthroplasty under general anesthesia will be randomly allocated into two equal groups of 30: Group DSG and Group PENG+LFCN. Total local anesthetic volume (30 mL) and active drug dose (75 mg bupivacaine) will be standardized across both groups to ensure rigorous blinding and high methodological quality. The primary outcome of the study is to compare total postoperative opioid (fentanyl) consumption within the first 24 hours. Secondary outcomes include postoperative pain scores evaluated via the Numerical Rating Scale (NRS) at rest and during movement, the presence and degree of quadriceps motor block, and opioid-related adverse effects (e.g., nausea, vomiting, pruritus).

Detailed description

This randomized, prospective, double-blind study is designed to evaluate and compare the postoperative analgesic efficacy of two different ultrasound-guided regional anesthesia techniques in patients undergoing elective hip arthroplasty under general anesthesia. Following institutional ethical approval and written informed consent, a total of 60 patients will be randomly allocated into two equal groups (n=30 per group): Group DSG (Deep Subgluteal Block) and Group PENG+LFCN (Pericapsular Nerve Group block combined with Lateral Femoral Cutaneous Nerve block). To optimize methodological quality, minimize bias, and maintain a strict double-blind design, both total local anesthetic volume (30 mL) and total active drug dose (75 mg bupivacaine) are perfectly standardized between the groups. All regional blocks will be performed by an experienced anesthesiologist using a high-frequency ultrasound transducer under sterile conditions after surgery is completed but before patient emergence/extubation. In Group DSG (n=30), patients will receive a total of 30 mL of 0.25% bupivacaine (15 mL administered beneath the gluteus minimus muscle and 15 mL beneath the gluteus medius muscle). No saline will be added to this group. In Group PENG+LFCN (n=30), patients will receive a total injection volume of 30 mL divided into two separate targets. First, the PENG block will be performed with 20 mL of 0.25% bupivacaine. Second, the LFCN block will be performed using a 10 mL volume consisting of 5 mL of 0.25% bupivacaine diluted with 5 mL of normal saline (0.9% NaCl), resulting in a final local anesthetic concentration of 0.125% bupivacaine at the LFCN site. Following block administration, a standard general anesthesia protocol will be applied. Postoperative patient-controlled analgesia (PCA) with intravenous fentanyl (10 mcg/mL solution, 10 mcg bolus, 10-minute lockout time, no basal infusion) will be initiated in the post-anesthesia care unit (PACU). Multi-modal analgesia will be supplemented with scheduled oral/IV ibuprofen (400 mg every 8 hours) and tramadol administered 30 minutes before the end of surgery. Postoperative pain assessments will be performed by a blinded independent investigator at 0 (PACU), 2, 4, 8, 16, and 24 hours using the Numerical Rating Scale (NRS) both at rest and during movement. In case of severe pain (NRS \>= 4), intravenous meperidine (0.5 mg/kg) will be administered as rescue analgesia. Cumulative opioid consumption, quadriceps motor strength (evaluated via the Oxford Muscle Strength Scale), and opioid-related adverse effects (such as postoperative nausea, vomiting, or pruritus) will be comprehensively monitored and recorded for the first 24 hours.

Interventions

DRUG0.25% Bupivacaine for Deep Subgluteal Block

Ultrasound-guided regional anesthesia. Patients receive 30 mL of 0.25% bupivacaine, divided as 15 mL beneath the gluteus minimus muscle and 15 mL beneath the gluteus medius muscle.

DRUG0.25% and 0.125% Bupivacaine for PENG+LFCN Block

Ultrasound-guided combination regional anesthesia. Patients receive a PENG block with 20 mL of 0.25% bupivacaine, combined with an LFCN block using 10 mL of 0.125% bupivacaine (5 mL of 0.25% bupivacaine diluted with 5 mL of 0.9% normal saline).

Sponsors

Medipol University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Masking description

The patient and the investigator assessing postoperative outcomes are blinded to the group allocation.

Intervention model description

Patients are randomly assigned to one of the two parallel groups to receive either ultrasound-guided Deep Subgluteal Block or a combination of PENG and LFCN blocks.

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Patients scheduled for elective total or partial hip arthroplasty under general anesthesia * American Society of Anesthesiologists (ASA) physical status I-III * Aged between 18 and 80 years * Able to understand the study procedures, give voluntary written informed consent, and operate a patient-controlled analgesia (PCA) device

Exclusion criteria

* Patient refusal or inability to provide informed consent * Pre-existing peripheral neuropathy, cognitive impairment, or psychiatric disorders * History of significant severe renal or hepatic failure * Allergy or hypersensitivity to amide-type local anesthetics or opioids * Infection, severe anatomic distortion, or previous surgery at the proposed block injection sites * History of substance abuse or chronic opioid use (defined as daily opioid use for \> 3 months prior to surgery)

Design outcomes

Primary

MeasureTime frameDescription
Cumulative Postoperative Opioid ConsumptionFirst 24 hours postoperativelyTotal intravenous fentanyl consumption (in micrograms) delivered via patient-controlled analgesia (PCA) within the first 24 hours postoperatively.

Secondary

MeasureTime frameDescription
Postoperative Pain ScoresPostoperative hours 0 (PACU), 2, 4, 8, 16, and 24Pain intensity evaluated at rest and during movement using the Numerical Rating Scale (NRS, 0 = no pain, 10 = worst imaginable pain).
Quadriceps Motor StrengthPostoperative hours 2, 4, 8, 16, and 24Assessment of quadriceps motor block evaluated using the Oxford Muscle Strength Scale (0 = total paralysis, 5 = normal strength).
Opioid-Related Adverse EffectsFirst 24 hours postoperativelyIncidence of opioid-related side effects including postoperative nausea, vomiting, pruritus, and respiratory depression.

Countries

Turkey (Türkiye)

Contacts

CONTACTYunus O Atalay, MD, Prof., DESAIC
yoatalay@medipol.edu.tr+90 212 453 4800

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 19, 2026